Dynavax makes Christine Larson CFO
This article was originally published in Scrip
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases, has appointed Christine Larson vice-president and chief financial officer. Ms Larson has a background in corporate finance and investment banking, and joins Dynavax from PDL Biopharma where she was responsible for leading financial and strategic planning, accounting and treasury.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.